Advertisement第118回日本精神神経学会学術総会

Abstract

第123巻第12号

※会員以外の方で全文の閲覧をご希望される場合は、「電子書籍」にてご購入いただけます。
Mismatch Negativity (MMN) as a Promising Translational Neurophysiological Biomarker in Schizophrenia
Patricia T. MICHIE1,3,4, Jaishre JALEWAe1, Lauren HARMS2,3,4, Juanita TODD1,3,4, Deborah HODGSON1,3,4
1 School of Psychological Sciences, College of Engineering, Science and Environment, University of Newcastle
2 School of Biomedical Science and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle
3 Centre for Brian and Mental Health Research, University of Newcastle
4 Hunter Medical Research Institute
Psychiatria et Neurologia Japonica 123: 824-841, 2021

 Mismatch negativity (MMN) is a neurophysiological response measured as an auditory event-related potential (ERP) generated automatically by the brain when a deviant sound occurs rarely and unpredictably amongst regular background sounds. A reduction in the amplitude of MMN in schizophrenia is one of the most replicated results in schizophrenia studies first reported approximately 30 years ago. Considering the large effect size of the MMN reduction and other characteristics of MMN in schizophrenia, it has been proposed that MMN have the status of a neurophysiological biomarker of the disorder. In this paper, we review the evidence that has accrued to support the assertion of biomarker status, and then evaluate what that means for diagnosis, prognosis, and prediction of medication response, but most importantly, its use as a translational tool in pre-clinical studies. Although considerable knowledge has accrued over the last decades about the optimal stimulus conditions for exposing MMN impairments in schizophrenia, the association with cognitive deficits and functional status, and the involvement of the glutamate NMDAr system, little is known about the neurobiological basis of MMN reduction in schizophrenia. Pre-clinical research using animal models is essential to make advances in this area. Fortunately, paradigms have been developed for use in the rat that strongly suggest that the rat brain is capable of generating the equivalent of a human MMN response or MMR. We review evidence supporting that a late component of MMR in the rat exhibits many of the characteristics of the human MMR. What is needed now is an animal model of schizophrenia that produces a robust and replicable reduction in this component that can be investigated using molecular approaches to support the development of novel pharmaceuticals to rescue MMR in these animals.

Keywords:mismatch negativity, MMN, schizophrenia, animal models of schizophrenia, pre-clinical>
Advertisement

ページの先頭へ

Copyright © The Japanese Society of Psychiatry and Neurology